Medtronic Reports Mixed Second Quarter Results
This article was originally published in The Gray Sheet
Executive Summary
Spine revenues of $782 million, for instance, declined 5% on a constant currency basis, while coronary revenues rose by 19% to $429 million, driven by global sales of the firm’s Resolute Integrity zotarolimus-eluting stent.
You may also be interested in...
FDA Audit Slows Down Medtronic Launch Plans For Low-Glucose-Suspend Diabetes System
A recent FDA inspection of Medtronic’s diabetes business identified quality systems deficiencies that are likely to delay the firm’s launch of its first-of-a-kind MiniMed 530G insulin pump/continuous glucose monitoring system.
Medtronic Puts Spine Business Under Close Evaluation
Medtronic may need to reassess the "strategy and approach” for its spine business if performance doesn't improve, CEO Omar Ishrak said last week. Ishrak did not take a divestiture off the table, but put more emphasis on the potential for internal restructuring.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.